Mimedx To Host Shareholder Call On January 18, 2018 To Update Progress On Multiple Clinical Studies And Status Of Patent Portfolio
The Company reported that "Pete" Petit, Chairman and CEO;
The Company expects the formal presentation to last approximately 45 minutes, after which the call will be open for questions and answers. The subject matter to be covered will include:
- Status of Plantar Fasciitis Phase 2B IND study, Plantar Fasciitis Phase 3 IND study, Achilles Tendonitis Phase 3 IND study, and Osteoarthritis IND Phase 2B study;
- Plans for submitting a Biologic License Application (BLA) to the
FDA for tendonitis when the Plantar Fasciitis and Achilles Tendonitis Phase 3 trials are completed; - Impact of Recent Successful Settlement of Patent Infringement Lawsuit; and
- Status of Incremental Health Plan Coverage as result of VLU Clinical Study
A listen-only simulcast of this
About
MiMedx® is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts.
View original content:http://www.prnewswire.com/news-releases/mimedx-to-host-shareholder-call-on-january-18-2018-to-update-progress-on-multiple-clinical-studies-and-status-of-patent-portfolio-300582262.html
SOURCE
Investor Contact: COCKRELL GROUP, Rich Cockrell, 877-889-1972, investorrelations@thecockrellgroup.com, cockrellgroup.com; Contact: Michael Senken, Phone: (770) 651-9100